Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

52.14.162.200
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Interstitial Lung Disease
Journal Scan

Case study: Interstitial lung disease after COVID-19 vaccination

Posted on

In this Case Based Discussion, the case of an 86-year-old man who developed weakness, dyspnoea, and fever the day after receiving a COVID-19 mRNA vaccine, is presented.

The patient was a non-smoker and did not have a history of cardiovascular, pulmonary, allergic, or connective tissue disease (CTD) problems. He reported no history of adverse events after receiving other vaccines, including an annual flu shot, and no recent environmental or chemical exposures.

At admission to the Emergency Department, his peripheral oxygen saturation was 80%.

-Advertisement-
-Advertisement-

Electrocardiograph and chest radiograph found sinus tachycardia and bilateral reticular opacities, respectively.

Despite starting on empirical antibiotics chest radiograph findings worsened, and bilateral diffuse ground-glass opacities with focal consolidations, centrilobular micronodules, and interlobular septal thickening were found on a chest CT.

The patient was diagnosed with COVID-19 vaccine-related ILD and treated with intravenous methylprednisolone at 1 mg/kg/day, which rapidly improved symptoms.

“A comprehensive review with a long-term follow-up about the safety of COVID-19 vaccines in older adults is lacking. This report suggests that healthcare professionals monitoring the adverse events should be vigilant for COVID-19 vaccine-related ILD, for a prompt diagnosis and timely treatment. Although vaccine-related ILD should be listed as an adverse reaction of the COVID-19 vaccine, we emphasize that the risk:benefit ratio remains firmly in favor of vaccination,” the authors wrote.

Read the full discussion here.

Reference
Park JY, Kim JH, Lee IJ, Kim HI, Park S, Hwang YI, Jang SH, Jung KS. COVID-19 vaccine-related interstitial lung disease: a case study. Thorax. 2021;thoraxjnl-2021-217609. doi: 10.1136/thoraxjnl-2021-217609. Epub ahead of print. PMID: 34362838.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-